<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787630</url>
  </required_header>
  <id_info>
    <org_study_id>NoHarm1</org_study_id>
    <nct_id>NCT01787630</nct_id>
  </id_info>
  <brief_title>To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy</brief_title>
  <acronym>NoHarm</acronym>
  <official_title>Initiating Phase II-III Study to Evaluate the Technique and Effects of Separating the Prostate From the Rectum With Hyaluronic Acid During Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Widmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ume책</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ume책 University</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dominating problem after local radiotherapy of prostate cancer is rectal toxicity. If
      the rectum could be completely moved out of the treated volume, a substantial decrease of
      rectal toxicity seems reasonable. In this study we will develop and evaluate a new
      transrectal injection technique where hyaluronic acid (HA) is injected in the space between
      the prostate and the rectum prior to external beam radiotherapy to increase the physical
      distance between prostate and rectum.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Remaining volume of HA</measure>
    <time_frame>24 month after end of radiotherapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement on the remaining volume of HA by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 month after end of radiotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient evaluation with questionnaires regarding Quality of Life and side effects after radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Injection in connection with ultrasound</description>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <other_name>NASHA Spacer Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified prostatic cancer

          -  Low or intermediate risk prostatic cancer

          -  Lymph node negative

          -  Suitable for radiotherapy

        Exclusion Criteria:

          -  Earlier treatment for prostatic cancer

          -  Unable to co-operate or suffering from any other form of disease that would interfere
             with the planned treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Widmark, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umea university, dept of oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Widmark, Prof MD</last_name>
    <phone>+46 90 785</phone>
    <phone_ext>2857</phone_ext>
    <email>anders.widmark@onkologi.umu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of oncology, Kalmar Hospital</name>
      <address>
        <city>Kalmar</city>
        <zip>SE-39244</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Lagerlund, MD</last_name>
      <email>magnus.lagerlund@ltkalmar.se</email>
    </contact>
    <investigator>
      <last_name>Magnus Lagerlund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of oncilogy, Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>SE-851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lars Beckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of oncology, University Hospital</name>
      <address>
        <city>Ume책</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Widmark, MD</last_name>
      <email>anders.widmark@onkologi.umu.se</email>
    </contact>
    <investigator>
      <last_name>Anders Widmark, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 6, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ume책 University</investigator_affiliation>
    <investigator_full_name>Anders Widmark</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Prostatic cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Hyaluronic acid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
